BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahn JY, Lee JS, Min HY, Lee HY. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer. Oncotarget. 2015;6:32622-32633. [PMID: 26416450 DOI: 10.18632/oncotarget.5327] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Jimura N, Fujii K, Qiao Z, Tsuchiya R, Yoshimatsu Y, Kondo T, Kanekura T. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. J Dermatol Sci 2021;101:194-201. [PMID: 33531202 DOI: 10.1016/j.jdermsci.2021.01.004] [Reference Citation Analysis]
2 Lee SH, Kim JM, Lee DG, Lee J, Park JG, Han TS, Cho HS, Cho YL, Bae KH, Park YJ, Lee SJ, Lee MS, Huh YM, Jo DY, Yun HJ, Jeon HJ, Kim N, Joo M, Kim JS, Lee HJ, Min JK. Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation. Cell Death Differ 2021;28:968-84. [PMID: 32989241 DOI: 10.1038/s41418-020-00628-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li M, Chen W, Zhang H, Zhang Y, Ke F, Wu X, Zhang Y, Weng M, Liu Y, Gong W. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Oncotarget 2016;7:83060-70. [PMID: 27825112 DOI: 10.18632/oncotarget.13067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
4 Zhang Y, Zhang TJ, Li XY, Liang JW, Tu S, Xu HL, Xue WH, Qian XH, Zhang ZH, Zhang X, Meng FH. 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents. Eur J Med Chem 2021;210:112988. [PMID: 33189438 DOI: 10.1016/j.ejmech.2020.112988] [Reference Citation Analysis]
5 Jin W. Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications. Cancers (Basel) 2020;12:E1339. [PMID: 32456226 DOI: 10.3390/cancers12051339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
6 Zhang L, Song R, Gu D, Zhang X, Yu B, Liu B, Xie J. The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell Biosci 2017;7:17. [PMID: 28413604 DOI: 10.1186/s13578-017-0145-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
7 Li Y, Chen Y, Qiu C, Ma X, Lei K, Cai G, Liang X, Liu J. 17-allylamino-17-demethoxygeldanamycin impeded chemotherapy through antioxidant activation via reducing reactive oxygen species-induced cell death. J Cell Biochem 2018. [PMID: 30378153 DOI: 10.1002/jcb.27397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Escalante PI, Quiñones LA, Contreras HR. Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX. Pharmaceutics 2021;13:75. [PMID: 33429840 DOI: 10.3390/pharmaceutics13010075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Ojima K, Ichimura E, Suzuki T, Oe M, Muroya S, Nishimura T. HSP90 modulates the myosin replacement rate in myofibrils. Am J Physiol Cell Physiol 2018;315:C104-14. [PMID: 29561661 DOI: 10.1152/ajpcell.00245.2017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Chauvin A, Bergeron D, Vencic J, Lévesque D, Paquette B, Scott MS, Boisvert FM. Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells. BMC Cancer 2022;22:363. [PMID: 35379199 DOI: 10.1186/s12885-022-09417-3] [Reference Citation Analysis]
11 Sreekumar R, Al-Saihati H, Emaduddin M, Moutasim K, Mellone M, Patel A, Kilic S, Cetin M, Erdemir S, Navio MS, Lopez MA, Curtis N, Yagci T, Primrose JN, Price BD, Berx G, Thomas GJ, Tulchinsky E, Mirnezami A, Sayan AE. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer. Mol Oncol 2021;15:2065-83. [PMID: 33931939 DOI: 10.1002/1878-0261.12965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Milczarek M, Rossowska J, Klopotowska D, Stachowicz M, Kutner A, Wietrzyk J. Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase. J Steroid Biochem Mol Biol 2019;190:139-51. [PMID: 30923017 DOI: 10.1016/j.jsbmb.2019.03.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
13 Wanders D, Hobson K, Ji X. Methionine Restriction and Cancer Biology. Nutrients 2020;12:E684. [PMID: 32138282 DOI: 10.3390/nu12030684] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
14 Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N. Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers (Basel) 2018;10:E240. [PMID: 30041457 DOI: 10.3390/cancers10070240] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
15 Wang L, Shi C, Yu J, Xu Y. FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-021-02372-2] [Reference Citation Analysis]
16 Bazzaz R, Bijanpour H, Pirouzpanah SMB, Yaghmaei P, Rashtchizadeh N. Adjuvant therapy with γ-tocopherol-induce apoptosis in HT-29 colon cancer via cyclin-dependent cell cycle arrest mechanism. J Biochem Mol Toxicol 2019;33:e22399. [PMID: 31587439 DOI: 10.1002/jbt.22399] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Xie Q, Wu MY, Zhang DX, Yang YM, Wang BS, Zhang J, Xu J, Zhong WD, Hu JN. Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivoWorld J Gastroenterol 2016; 22(32): 7342-7352 [PMID: 27621580 DOI: 10.3748/wjg.v22.i32.7342] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
18 Grumetti L, Lombardi R, Iannelli F, Pucci B, Avallone A, Di Gennaro E, Budillon A. Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors. Cancers 2022;14:695. [DOI: 10.3390/cancers14030695] [Reference Citation Analysis]
19 Do KT, O'Sullivan Coyne G, Hays JL, Supko JG, Liu SV, Beebe K, Neckers L, Trepel JB, Lee MJ, Smyth T, Gannon C, Hedglin J, Muzikansky A, Campos S, Lyons J, Ivy P, Doroshow JH, Chen AP, Shapiro GI. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2020;86:815-27. [PMID: 33095286 DOI: 10.1007/s00280-020-04176-z] [Reference Citation Analysis]
20 Yun CW, Kim HJ, Lim JH, Lee SH. Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy. Cells 2019;9:E60. [PMID: 31878360 DOI: 10.3390/cells9010060] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
21 Monica V, Lo Iacono M, Bracco E, Busso S, Di Blasio L, Primo L, Peracino B, Papotti M, Scagliotti G. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines. Oncotarget 2016;7:76577-89. [PMID: 27391433 DOI: 10.18632/oncotarget.10428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
22 Regmi P, Lai KC, Liu CJ, Lee TC. SAHA Overcomes 5-FU Resistance in IFIT2-Depleted Oral Squamous Cell Carcinoma Cells. Cancers (Basel) 2020;12:E3527. [PMID: 33256074 DOI: 10.3390/cancers12123527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Di Paolo A, Orlandi P, Di Desidero T, Danesi R, Bocci G. Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. Oncol Res 2017;25:1129-40. [PMID: 28109077 DOI: 10.3727/096504017X14841698396900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
24 Vaghari-Tabari M, Majidinia M, Moein S, Qujeq D, Asemi Z, Alemi F, Mohamadzadeh R, Targhazeh N, Safa A, Yousefi B. MicroRNAs and colorectal cancer chemoresistance: New solution for old problem. Life Sci 2020;259:118255. [PMID: 32818543 DOI: 10.1016/j.lfs.2020.118255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
25 Chen S, Duan Y, Wu Y, Yang D, An J. A Novel Integrated Metabolism-Immunity Gene Expression Model Predicts the Prognosis of Lung Adenocarcinoma Patients. Front Pharmacol 2021;12:728368. [PMID: 34393804 DOI: 10.3389/fphar.2021.728368] [Reference Citation Analysis]
26 Liang X, Shi H, Yang L, Qiu C, Lin S, Qi Y, Li J, Zhao A, Liu J. Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells. Br J Cancer 2017;116:903-11. [PMID: 28222070 DOI: 10.1038/bjc.2017.32] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
27 Varghese V, Magnani L, Harada-Shoji N, Mauri F, Szydlo RM, Yao S, Lam EW, Kenny LM. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. Sci Rep 2019;9:1505. [PMID: 30728402 DOI: 10.1038/s41598-018-38017-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
28 Mohammadian M, Zeynali S, Azarbaijani AF, Khadem Ansari MH, Kheradmand F. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. Res Pharm Sci 2017;12:517-25. [PMID: 29204180 DOI: 10.4103/1735-5362.217432] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
29 Yokoyama R, Kojima H, Takai R, Ohta T, Maeda H, Miyashita K, Mutoh M, Terasaki M. Effects of CLIC4 on Fucoxanthinol-Induced Apoptosis in Human Colorectal Cancer Cells. Nutr Cancer 2021;73:889-98. [PMID: 33703973 DOI: 10.1080/01635581.2020.1779760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Kensara OA, El-Shemi AG, Mohamed AM, Refaat B, Idris S, Ahmad J. Thymoquinone subdues tumor growth and potentiates the chemopreventive effect of 5-fluorouracil on the early stages of colorectal carcinogenesis in rats. Drug Des Devel Ther 2016;10:2239-53. [PMID: 27468227 DOI: 10.2147/DDDT.S109721] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]